IGF-I REGULATES CELLULAR proliferation in two ways: 1) it is mitogenic for many cells and 2) it promotes the increase in cell size that is required for cell division. Binding of IGF-I to the cognate IGF-I receptor stimulates the intrinsic tyrosine kinase activity of the receptor. Mutational analysis has identified several tyrosine phosphorylation sites within the carboxy terminus of the IGF-I receptor ␤-subunit that confer specificity for the proliferative effects elicited in response to receptor autophosphorylation: Tyr 950 , Tyr 1131 , Tyr
1135
, and Tyr 1136 (20, 28, 29) . The activated IGF-I receptor tyrosine kinase has several known primary substrates, including the insulin receptor substrate family of proteins, Src-homology domain carboxy terminus, Grb2-associated binder 1, hepatocyte plasma membrane ecto ATPase (pp120/HA4), and G2 kDa GAP-associated docking protein (p62DOK). Once phosphorylated, these docking proteins activate downstream intracellular signaling through the phosphatidylinositol 3-kinase (PI3K) or Grb2-SOS pathways that ultimately leads to cellular proliferation. The specific pathways activated by IGF-I and the roles of these pathways in mediating the proliferative response to IGF-I depend on the cell type. We have previously shown that in human intestinal smooth muscle cells, like skeletal muscle cells and vascular smooth muscle cells, IGF-I activates both the ERK1/2 and PI3K pathways that regulate growth (11, 14, 24) . The particular importance of IGF-I in regulating the growth of intestinal smooth muscle is demonstrated by the hyperplasia that occurs in both intestinal and vascular smooth muscle tissues of transgenic animals overexpressing an IGF-I cDNA (31, 48) . The pathways mediating intestinal smooth muscle proliferation are likely to play an important role in the setting of Crohn's disease, in which IGF-I expression is upregulated and may contribute to the hyperplasia of smooth muscle that contributes to the formation of intestinal strictures (53) .
Two isoforms of the ribosomal S6K1 are derived from alternative splicing at the amino terminus: p85S6K1␣I and p70S6K1␣II (35, 36) . The p70S6K1␣II isoform (p70S6 kinase) is mainly cytosolic, whereas the p85S6K1␣I isoform is predominantly nuclear. p70S6 kinase, a serine/threonine protein kinase, is activated by growth factors and plays a central role in cell growth and proliferation by mediating the phosphorylation of the 40S ribosomal protein, S6, thereby enabling efficient translation of 5Ј-terminal oligopyrimidine tract mRNAs . This class of mRNAs encodes for numerous components of the protein synthesis machinery: ribosomal proteins and elongation factors. A second S6K homologue, S6K2, was identified in S6K1-deficient mice that exhibited a phenotype of dimin-ished but not absent growth compared with that of wild-type mice (42) . In S6K1-deficient mice, S6K2 expression was upregulated and provided partial compensation for the absence of S6K1. S6K2 also exists as two isoforms, p60S6K2␤I and p54S6K2␤II. Both S6K2 isoforms contain a carboxy-terminal nuclear localization signal not found in S6K1 and are therefore localized predominantly in the nucleus.
Activation of p70S6 kinase depends on the sequential phosphorylation of four sets of serine/threonine sites by several independently regulated kinases (49) . The initial step in p70S6 kinase activation involves the phosphorylation of serine/threonine residues in the autoinhibitory pseudosubstrate domain (Ser , and Thr 421 ) and in the catalytic domain extension (Thr 390 and Ser 394 ) under the control of proline-directed kinases (7, 30 ) phosphorylation (50) . Dual phosphorylation of Thr 229 and Thr 389 fully activates p70S6 kinase.
p70S6 kinase participates in PI3K-dependent regulation of muscle growth by IGF-I in rat and porcine vascular smooth muscle cells (14, 18) and in L6A1 skeletal myoblasts (11) . Although several signaling intermediates lying downstream of PI3K have been shown to regulate the activity of p70S6 kinase in other muscle types [PDK-1, Akt, and the mammalian target of rapamycin (mTOR)] it is not known whether IGF-I activates p70S6 kinase in human intestinal smooth muscle cells or the sequence of signaling events emanating from PI3K that regulate p70S6 kinase activity and muscle cell growth.
This study shows that, in human intestinal smooth muscle cells, IGF-I causes phosphorylation of multiple serine/threonine residues on p70S6 kinase that result in its activation. Serine/threonine residues within the autoinhibitory domain are phosphorylated in a PI3K-dependent fashion involving PKC-. p70S6 kinase-(Ser 389 ) and p70S6 kinase(Thr 229 ) in the catalytic domain are phosphorylated in a PI3K-dependent, PDK-1-dependent fashion. Whereas IGF-I-induced ERK1/2 and PI3K activation jointly stimulate muscle cell proliferation, active p70S6 kinase is required for growth to occur regardless of the pathway involved.
IGF-I also elicits PI3K-dependent, PDK-1-dependent Akt(Ser 308 ) phosphorylation and subsequent Akt-(Ser 473 ) autophosphorylation that leads to phosphorylation of mTOR on Ser 2448 . Although mTOR kinase activity is required for stimulation of cell growth, IGF-I-induced, Akt-dependent mTOR(Ser 2448 ) phosphorylation is regulated independently of mTOR kinase activity and is not required for IGF-I-mediated p70S6 kinase activation and proliferation to occur.
METHODS

Culture of isolated smooth muscle cells from normal human jejunum.
Muscle cells were isolated and cultured from the circular muscle layer of human jejunum as described previously (21, 22, 24) . Briefly, 4-to 5-cm segments of normal jejunum were obtained from patients undergoing surgery for morbid obesity according to a protocol approved by the University Office of Research Subject Protection. After the segments were opened along the mesenteric border, the mucosa was dissected away and the remaining muscle layer was cut into 2 ϫ 2-cm strips. Slices were obtained separately from the circular layer by using a Stadie-Riggs tissue slicer. The slices were incubated overnight at 37°C in 20 ml of DMEM plus 10% fetal bovine serum (DMEM-10) containing 200 U/ml penicillin, 200 g/ml streptomycin, 100 g/ml gentamycin, and 2 g/ml amphotericin B, to which was added 0.0375% collagenase (CLS type II) and 0.1% soybean trypsin inhibitor. Muscle cells dispersed from the circular layer were harvested by filtration through 500-m Nitex mesh and centrifuged at 150 g for 5 min. Cells were resuspended and washed twice by centrifugation at 150 g for 5 min. After resuspension in DMEM-10 containing the same antibiotics, the cells were plated at a concentration of 5 ϫ 10 5 cells/ml as determined by counting in a hemocytometer. Cultures were incubated in a 10% CO 2 environment at 37°C. DMEM-10 medium was replaced every 3 days until the cells reached confluence.
Primary cultures of muscle cells were passaged on reaching confluence by first being washed three times with PBS. After the PBS was removed, cells were treated for 2 min with 0.05% trypsin and 0.53 mM EDTA. The trypsin activity was neutralized by addition of a fourfold excess of DMEM-10. The resulting cell suspension was centrifuged at 350 g for 10 min at 4°C. The pellet was resuspended in DMEM-10 at a concentration of 2.5 ϫ 10 6 cells/ml and plated in the appropriate cultureware. The medium was changed after 24 h. All subsequent studies were performed in first-passage cultured cells after 7 days, at which time the cells were confluent. We have previously shown that these cells express a phenotype characteristic of intestinal smooth muscle as determined by immunostaining for smooth muscle markers and expression of ␥-enteric actin. Epithelial cells, endothelial cells, neurons, and interstitial cells of Cajal were not detected in these cultures (21, 46) .
[ 3 H]thymidine incorporation assay. Proliferation of smooth muscle cells in culture was measured by the incorporation of [ 3 H]thymidine as described previously (21, 24, 25) . Briefly, the cells were washed free of serum and incubated for 24 h in serum-free DMEM. The quiescent muscle cells were incubated for an additional 24 h with a maximally effective concentration of IGF-I (100 nM) in the presence and absence of various test agents. During the final 4 h of this incubation period, 1 Ci/ml [ 3 H]thymidine was added to the medium. [ 3 H]thymidine incorporation into the perchloric acid extractable pool was used as a measure of DNA synthesis.
Measurement of p70S6 kinase activity by in vitro kinase assay. The activity of p70S6 kinase was assayed by using an immune complex in vitro kinase assay by modification of the methods of Zhang et al. (52) . Briefly, confluent muscle cells were rendered quiescent by incubation in serum-free DMEM for 24 h. Cells were stimulated with IGF-I (100 nM) for the indicated periods of time (0-24 h) in the presence or absence of various inhibitors. The reaction was terminated by wash-ing the cells in ice-cold PBS. The cells were lysed in buffer consisting of (in mM): 50 Tris (pH 7.5), 1 EDTA, 1 EGTA, 0.5 sodium orthovanadate, 50 NaF, 5 sodium pyrophosphate, 10 sodium glycerol phosphate, and 0.1 PMSF, with 0.1% 2-mercaptoethanol, 1% Triton X-100, 1 g/ml aprotinin, and 1 g/ml leupeptin. Cell lysates were clarified by centrifugation, and aliquots of the supernatant containing equal amounts of protein (200 g) were incubated with 4 g of p70S6 kinase antibody coupled to protein A/G agarose beads for 2 h at 4°C. The protein A/G agarose-protein immune complexes were washed once with lysis buffer containing 0.5 M NaCl, twice with lysis buffer alone, and finally in assay buffer consisting of (in mM) : Measurement of PI3K activity by in vitro kinase assay. PI3K activity was measured as described previously (24) . Briefly, quiescent muscle cells growing in 100-mm dishes were stimulated for 30 min with IGF-I (100 nM) in the presence and absence of various inhibitors. The reaction was terminated by rapidly washing cells with 4°C PBS and by lysis of the cells. Lysis buffer consisted of (in mM): 50 Tris ⅐ HCl (pH 7.4), 150 NaCl, 1 Na2VO3, 2 EDTA, 1 MgCl2, and 1 CaCl 2, with 30 nM leupeptin, 1% trasylol (wt/vol), and 1% NP-40 (vol/vol). DNA in the lysate was sheared by passage through a 22-gauge needle, and the lysate was incubated for 20 min at 4°C. Following this incubation, the lysate was centrifuged at 12,000 g for 20 min at 4°C. Aliquots of lysate containing equal amounts of protein were incubated with 25 l of agarose-conjugated antibody to phosphotyrosine (PY20) with gentle mixing for 2 h at 4°C. The beads were collected by centrifugation at 12,000 g for 5 min at 4°C and washed three times with lysis buffer and two times with kinase assay buffer. Kinase assay buffer consisted of (in mM): 50 Tris ⅐ HCl (pH 7.8), 50 NaCl, 2 MgCl2, and 0.5 EDTA. After the final washing, the beads were resuspended in 30 l of kinase assay buffer to which 10 l of sonicated 1 mg/ml phosphatidylinositol was added. The reaction was initiated by the addition of 5 l of 50 mM ATP containing 0.5 Ci [␥-32 P]ATP and was continued for 10 min at 30°C. The reaction was terminated by addition of 0.5 ml of 1 N HCl and 2 ml of chloroform-methanol (2:1, vol/vol). Phospholipids were recovered from the lower organic phase and dried under N2 gas. The dried phospholipids were dissolved in chloroform and spotted on Silica H gel TLC plates impregnated with 1% potassium oxalate. Chromatograms were developed in chloroform-methanol-28% NH3-water (70:100:15:25, vol/vol). The plates were dried, and the spots corresponding to authentic PIP3 were visualized and quantitated by using a PhosphorImager (Packard Instruments, Meridien, CT). Results are expressed as the increase in [ 32 P] incorporation into PI-3-P above basal values.
Measurement of PDK-1 activity by in vitro kinase assay. The activity of PDK-1 was measured by an immune complex in vitro kinase assay according to the methods of Fujita et al. (16) . Briefly, quiescent muscle cells were incubated for 30 min with 100 nM IGF-I. The reaction was terminated by washing cells with ice-cold PBS. The cells were lysed in buffer consisting of (in mM): 50 Tris (pH 7.5), 1 EDTA, 1 EGTA, 50 NaF, 1 sodium orthovanadate, 5 sodium pyrophosphate, and 10 sodium ␤-glycerol phosphate, with 0.1% 2-mercaptoethanol (vol/vol), 0.1% Triton X-100 (vol/vol), and 1 M Microcystin LR. Following the addition of 50 l of protein G agarose, the lysates were clarified by centrifugation at 4°C. Protein G-antibody complexes were simultaneously prepared by incubation of 4 g of anti-PDK-1 antibody (or normal sheep IgG as negative control) with 100 l of a 50% slurry of protein G agarose beads and 250 l of lysis buffer overnight at 4°C. Protein G-antibody complexes were washed twice with lysis buffer to remove weakly bound antibody by centrifugation at 14,000 rpm. Precleared IGF-I-stimulated cell lysates containing 1 mg of protein were added to the protein G/antibody complexes and incubated for 2 h at 4°C to immunoprecipitate active PDK-1. The resulting immune complexes were washed twice with lysis buffer and twice with PDK-1 assay buffer. PDK-1 assay buffer consisted of (in mM): 50 Tris ⅐ HCl (pH 7.5), 0.1 EDTA, 0.1 EGTA, 10 magnesium acetate, and 0.1 ATP, with 1% 2-mercaptoethanol (vol/vol), 2.5 M PKI, and 1 M Microcystin LR. The resulting PDK-1 immune complexes were resuspended in 20 l of PDK-1 assay buffer, and inactive serum-and glucocorticoid-dependent protein kinase (SGK1; ⌬1-60, S422D; 500 ng) was added to the immunoprecipitated PDK-1 to be activated by incubation for 30 min at 30°C. The final assay reaction was carried out in a total volume of 50 l. The reaction was initiated by addition of 4 nmol of Akt/SGK substrate peptide (RPRAATF) and 10 Ci of [␥-
32 P]ATP and continued for 10 min at 30°C. The reaction was terminated by centrifugation at 14,000 rpm and spotting of 25-l aliquots on P81 phosphocellulose paper. The phosphocellulose paper was washed three times with 0.75% phosphoric acid and one time with acetone, dried, transferred to scintillation vials, and counted on a ␤-scintillation counter. The results were corrected for endogenous substrates by subtraction of values obtained after immunoprecipitation with normal sheep IgG. Values were expressed in picomoles of phosphate incorporated into peptide substrate per minute per milligram of protein.
Western blot analysis. The phosphorylation of PDK-1, Akt, mTOR, PKC-, and p70S6 kinase on specific residues was measured by Western blot analysis by using standard methods (9, 24, 26) . Briefly, confluent muscle cells were rendered quiescent by incubation for 24 h in serum-free medium. The cells were stimulated with recombinant human IGF-I for 30 min (the time of peak p70S6 kinase activation). The cells were rapidly washed with ice-cold PBS and lysed in sample buffer. Lysates were boiled for 5 min, and equal amounts of total cell protein were separated with SDS-PAGE under denaturing conditions. After the proteins were electrotransferred to nitrocellulose, the membranes were incubated overnight with a 1:1,000-1:2,000 dilution of antibodies recognizing phosphorylated (activated) signaling intermediates: . Bands of interest were visualized with enhanced chemiluminescence. Nitrocellulose membranes were stripped and reblotted to determine levels of total (phosphorylated and nonphosphorylated) pro-tein using antibodies recognizing PDK-1, Akt, mTOR, PKC-, and p70S6 kinase.
Expression of kinase-inactive Akt. Substitution of methionine for lysine at residue 179 (K179M) results in a kinaseinactive Akt1, which when expressed in cells exerts a dominant-negative effect (43) . cDNA for Myc-His-tagged kinaseinactive Akt1(K179M) in the pUSEamp(ϩ) expression vector was purified, and muscle cells growing in six-well plates were transiently transfected with 1 g of pUSEamp(ϩ)-Akt1(K179M) cDNA or with pUSEamp(ϩ) vector alone as a control by using a LipofectAMINE PLUS reagent kit (Life Technologies). Cells were incubated for 3 h at 37°C with the transfection reagent-DNA complexes. The DNA-containing medium was replaced with DMEM plus 10% FCS. After 48 h incubation, the expression of Akt1(K179M) was confirmed by Western blot analysis using an anti-Myc tag antibody, and the kinase-inactive effect of this mutation on IGF-I signaling was confirmed by analysis of Akt ( ), and anti-rabbit IgG horseradish peroxidase were obtained from Cell Signaling Technology (Beverly, MA); rabbit polyclonal antibody to phospho-p70S6 kinase(Thr 229 ) was obtained from R&D Systems (Minneapolis, MN); agarose-conjugated mouse monoclonal antibody to phosphotyrosine (PY20) was obtained from Transduction Laboratories (Lexington, KY); mouse monoclonal antibody to the Myc tag on Akt1(K179M), PDK-1 kinase, and p70S6 kinase assay kits were obtained from Upstate Biotechnology (Lake Placid, NY); myristoylated PKC-pseudosubstrate (myr-PKC--PS) was obtained from Biomol (Plymouth Meeting, PA); the inhibitors LY-294002, U-1026, SB-203580, N␣-tosyl-Phe chloromethyl ketone (TPCK), Microcystin LR, and rapamycin were obtained from Calbiochem (San Diego, CA); Western blotting materials and DC protein assay kit were obtained from Bio-Rad Laboratories (Hercules, CA); and plastic cultureware was obtained from Corning (Corning, NY). All other chemicals were obtained from Sigma (St Louis, MO).
RESULTS
Role of p70S6 kinase in IGF-I-induced growth.
We have previously shown (24) (Fig. 1A) . The role of Akt was identified in cells transiently transfected with the kinase-inactive Akt1(K179M) mutant. In cells expressing Akt1(K179M), the ability of IGF-I to stimulate [ 3 H]thymidine incorporation was not affected (225 Ϯ 25% above basal; vector ϭ 195 Ϯ 15% above basal) (Fig. 1B) . The results implied that IGF-Iinduced proliferation mediated by the PI3K signaling pathway is PDK-1 dependent and PKC-dependent but does not require Akt activation.
IGF-I activates p70S6 kinase. The ability of growth factors to fully stimulate p70S6 kinase activity involves the sequential phosphorylation of distinct sets of serine/threonine residues within p70S6 kinase. Phosphorylation of serine/threonine residues in the autoinhibitory domain of p70S6 kinase (e.g., Thr 421 and Ser
424
) relieves pseudosubstrate inhibition of the catalytic domain and is a prerequisite for phosphorylation of Thr 229 in the activation loop of the catalytic domain and of Thr 389 in the carboxy-terminal extension of the catalytic domain (1, 30, 49, 50) .
Our initial studies showed that p70S6 kinase activity was required for IGF-I to stimulate growth of human intestinal smooth muscle cells. The ability of IGF-I to activate p70S6 kinase in human intestinal muscle cells was therefore examined in two complementary ways. In the first, the ability of IGF-I to elicit phosphorylation of three specific regions of p70S6 ki- (Fig. 2, A and B (Fig. 2C) .
Incubation of confluent human intestinal smooth muscle cells with IGF-I for increasing periods of time (0-24 h) elicited time-dependent activation of p70S6 kinase. Activation of p70S6 kinase was also rapid, occurring within 5 min, was maximal within 30 min (46.0 Ϯ 2.5 pmol phosphate ⅐ min Ϫ1 ⅐ mg protein Ϫ1 above basal; basal activity ϭ 14.9 Ϯ 0.9 pmol phosphate ⅐ min Ϫ1 ⅐mg protein
Ϫ1
) and was sustained at submaximal levels for up to 24 h (Fig. 3A) . When measured at the 30-min maximum, activation of p70S6 kinase by IGF-I (1-100 nM) was concentration dependent (Fig. 3B) .
Mechanisms , and Thr 389 was measured by Western blot analysis, and activation of p70S6 kinase was measured by using in vitro kinase assay.
Phosphorylation of p70S6 kinase(Ser 421 /Thr 424 ) in response to 100 nM IGF-I (320 Ϯ 25% above basal) was inhibited by the PI3K inhibitor LY-294002 (10 M), the p70S6 kinase inhibitor rapamycin (10 nM), and the PKC-inhibitor myr-PKC--PS (15) but was not affected by the PDK-1 inhibitor TPCK (5), MKK1/2 inhibitor U-1026 (1 M), or p38 MAPK inhibitor SB-203580 (Fig. 4 and Table 1 ). Phosphorylation of p70S6 kinase(Thr 229 ) by IGF-I (220 Ϯ 20% above basal) was inhibited by the PI3K inhibitor, the PDK-1 inhibitor, the p70S6 kinase inhibitor, and the PKC-inhibitor but was not affected by the MKK1/2 inhibitor or the p38 MAPK inhibitor (Fig. 4 and Table 1 ). Phosphorylation of p70S6 kinase(Thr 389 ) by IGF-I (590 Ϯ 40% above basal) followed a similar pattern to that observed for p70S6 kinase(Thr 229 ) and was also inhibited by the PI3K inhibitor, the PDK-1 inhibitor, the p70S6 kinase inhibitor, and the PKC-inhibitor but was not affected by the MKK1/2 inhibitor or the p38 MAPK inhibitor (Fig. 4 and Table 1 Ϫ1 ⅐ mg protein Ϫ1 above basal) was inhibited by the PI3K inhibitor, the PDK-1 inhibitor, the PCK-inhibitor, and the p70S6 kinase inhibitor but was not affected by the MKK1/2 inhibitor or the p38 MAPK inhibitor (Fig. 4 and Table 1 ). The results implied that PI3K, PDK-1, and PKC-but not ERK1/2 or p38 MAPK participate in IGF-I-induced activation of p70S6 kinase.
PI3K-dependent signaling intermediates activated by IGF-I. The pattern of inhibition of IGF-I-induced p70S6 kinase phosphorylation, p70S6 kinase activation, and growth suggested that PI3K and PDK-1 play essential roles in these processes, as does PKC-, albeit to a lesser extent. The sequence of events initiated by IGF-I was therefore also investigated by using several complementary techniques. Activation of PI3K and PDK-1 in response to IGF-I was measured by using the in vitro kinase assay as had been done for p70S6 kinase. IGF-I stimulated phosphorylation of signaling intermediates: PDK-1(Ser 248 ), Akt(Ser 473 ), and mTOR-(Ser 2448 ) were measured by using phosphospecific antibodies in Western blot analysis. The sequence of signaling events initiated by IGF-I was then determined with the use of selective inhibitors.
We have previously shown that IGF-I elicits timedependent and concentration-dependent activation of PI3K (24) that was rapid, occurring within 5 min, was . The MKK1/2 and p38 MAPK inhibitors had no effect on IGF-I-induced phosphorylation of p70S6 kinase. Quantitative analysis of these data is provided in Table 1 . maximal within 10 min, and was sustained for up to 60 min. The results of the present study show that incubation of muscle cells with 100 nM IGF-I for 30 min increased PI3K activity by 680 Ϯ 90% above basal levels. IGF-I-induced activation of PI3K was inhibited 89 Ϯ 5% by the PI3K inhibitor but was not affected by the PDK-1 inhibitor, the p70S6 kinase inhibitor, or the PKC-inhibitor ( Table 2 ). Inhibitors of MKK1/2 and p38 MAPK also did not affect IGF-I-stimulated PI3K activity. The results implied that PI3K activation preceded activation of the other kinases (PDK-1, p70S6 kinase, and PKC-).
Incubation of quiescent muscle cells with 100 nM IGF-I for increasing periods of time (0-24 h) elicited time-dependent activation of PDK-1. IGF-I-induced PDK-1 activation was rapid, occurring within 5 min, was maximal within 30 min [6.29 Ϯ 0.10 pmol phosphate ⅐ min Ϫ1 ⅐ mg protein Ϫ1 above basal (basal ϭ 0.54 Ϯ 0.12 pmol phosphate ⅐ min Ϫ1 ⅐ mg protein
)], and was sustained at submaximal levels for up to 24 h (Fig. 3A) . When measured at the 30-min peak, IGF-Iinduced activation of PDK-1 was concentration dependent (Fig. 3B) like that observed for PI3K and p70S6 kinase. The time course of IGF-I-induced activation of PDK-1 was most similar to that of p70S6 kinase and peaked later than PI3K activation induced by IGF-I. IGF-I elicited concentration-dependent activation of all three kinases (PI3K, PDK-1, and p70S6 kinase).
IGF-I (100 nM, 30 min) also increased phosphorylation of PDK-1(Ser 241 ) by 74 Ϯ 7% above basal. Phosphorylation of PDK-1(Ser 241 ) and activation of PDK-1 by IGF-I were abolished by the PI3K inhibitor or by the PDK-1 inhibitor, were partly inhibited by the PKCinhibitor, but were not affected by the p70S6 kinase inhibitor (Fig. 5 and Table 2 ). The inhibitors of MKK1/2 and p38 MAPK did not affect IGF-I-stimulated PDK-1 phosphorylation or activity. Together, the results implied that PDK-1 activation occurred downstream of PI3K activation and was partly dependent on PKC-activation. IGF-I-induced activation of p70S6 kinase, in turn, was PI3K dependent and PDK-1 dependent.
IGF-I stimulated the phosphorylation of PKC-/ (Thr 410 /Thr 403 ) by 120 Ϯ 20% above basal. IGF-Iinduced phosphorylation of PKC-/(Thr 410 /Thr 403 ) was inhibited by the PI3K inhibitor and by the PDK-1 inhibitor but was not affected by the PKC-inhibitor, the p70S6 kinase inhibitor, the MKK1/2 inhibitor, or the p38 MAPK inhibitor (Fig. 5 and Table 2 ). The ability of the PKC-inhibitor myr-PKC--PS to block downstream effects mediated by PKC-without affecting phosphorylation of PKC-/(Thr 410 /Thr 403 ) is expected on the basis of its mechanism of action and is consistent with its effects in previous studies (15) .
IGF-I also stimulated the phosphorylation of Akt- Values are means Ϯ SE of 3-6 experiments. Results are expressed as the percent inhibition of response to 100 nM IGF-I for 30 min in either relative densitometric units from Western blot analysis using either phosphorylation state-specific antibodies (see Fig. 4 for representative blots) or pmol PO4 ⅐ min Ϫ1 ⅐ mg protein Ϫ1 from kinase assay of p70S6 kinase activity. PI3K, phosphatidylinositol 3-kinase; PDK, phosphoinositide-dependant kinase; MKK, MAP kinase kinase. * P Ͻ 0.05 vs. control. 
Table 2. Effect of various inhibitors on IGF-I-induced PI3K activation, PDK-1 activation, and phosphorylation of downstream signaling intermediates
Values are means Ϯ SE of 3-6 experiments. Results are expressed as the %inhibition of response to 100 nM IGF-I for 30 min in either pmol PO4 ⅐ min Ϫ1 ⅐ mg protein Ϫ1 measured by in vitro kinase assay of PI3K or PDK-1 kinase activity or in relative densitometric units from Western blot analysis using phosphorylation state-specific antibodies (see Fig. 5 for representative blots). * P Ͻ 0.05. phosphorylation of mTOR(Ser 2448 ) was inhibited by the PI3K inhibitor and by the PDK-1 inhibitor but was not affected by the PKC-inhibitor, the MKK1/2 inhibitor, or the p38 MAPK inhibitor. The p70S6 kinase inhibitor had only a modest effect on IGF-I-induced mTOR(Ser 2448 ) phosphorylation (Fig. 5 and Table 2 ). The results implied that IGF-I-stimulated mTOR(Ser 2448 ) phosphorylation occurred downstream of PI3K and PDK-1.
Effects of expression of a kinase-inactive Akt. Our initial studies showed that, although IGF-I elicited PI3K-dependent and PDK-1-dependent phosphorylation of Akt(Ser 473 ) (Fig. 5 and Table 2 ), a kinaseinactive Akt mutant did not affect IGF-I induced, PI3K-dependent proliferation (Fig. 1B) . The mechanisms leading to IGF-I-induced activation of Akt and the participation of Akt in IGF-I-induced p70S6 kinase activation were examined further in human intestinal muscle cells transfected with kinase-inactive Akt1(K179M) or empty vector.
The expression of Akt1(K179M) was confirmed by identification of the Myc tag by Western blot analysis (Fig. 6A) . The ability of kinase-inactive Akt1(K179M) to block IGF-I-induced Akt(Ser ) (vector ϭ 265 Ϯ 31% above basal) was inhibited 87 Ϯ 3% in cells transfected with kinase-inactive Akt1(K179M) (Fig. 6,  A and B) . Interestingly, in contrast to phosphorylation (210 Ϯ 40% above basal; vector ϭ 240 Ϯ 40% above basal), and Thr 389 (560 Ϯ 80% above basal; vector ϭ 580 Ϯ 30% above basal) and to increase p70S6 kinase activity by 25.6 Ϯ 1.5 pmol phosphate 4 ⅐ min Ϫ1 ⅐ mg protein Ϫ1 above basal (vector ϭ 23.6 Ϯ 2.7 pmol PO 4 ⅐ min Ϫ1 ⅐ mg protein Ϫ1 above basal; Fig. 6D ). The results implied that, although IGF-I elicits phosphorylation of Akt and downstream Akt-dependent phosphorylation of mTOR(Ser 2448 ), these events are not required for IGF-I-induced p70S6 kinase activation, similar to the Akt-independent nature of IGF-I-induced [ 3 H]thymidine incorporation.
DISCUSSION
IGF-I initiates a sequence of signaling events that culminates in cellular proliferation. A key component of this process is the activation of p70S6 kinase. p70S6 kinase regulates phosphorylation of the 40S ribosomal protein S6, a process that enables efficient translation of 5-TOPs and progression through the G 1 phase of the cell cycle. We have previously shown that IGF-I stimulates proliferation of human intestinal smooth muscle cells (22, 24) by activating both PI3K and ERK1/2. In these cells, these two pathways are distinct and jointly mediate the effects of IGF-I on growth. Phosphorylation of PI3K by IGF-I results in the production of PIP 3 (24) . PIP 3 , the major lipid product of activated PI3K (and to a lesser extent PIP 2 ), regulates both the localization, by stimulating plasma membrane association, and the activation, by facilitating phosphorylation, of downstream signaling molecules such as PDK-1, Akt, Table 2. and PKC-that leads to p70S6 kinase phosphorylation and activation.
In the present study, the PI3K-dependent signaling events activated by IGF-I that regulate p70S6 kinase activity and cell proliferation have been elucidated. IGF-I causes the sequential phosphorylation of PI3K, PDK-1, Akt, and mTOR. PI3K and PDK-1 activation mediate IGF-I-induced p70S6 kinase activation and regulate proliferation. Akt activation via PDK-1, although sufficient to modestly increase the levels of mTOR(Ser 2448 ) phosphorylation, is not required for IGF-I-induced p70S6 kinase activation or growth to occur. Moreover, mTOR kinase activity is required for IGF-I-induced cell proliferation but is distinct from the state of mTOR(Ser 2448 ) phosphorylation and is not regulated by Akt. IGF-I-induced, PI3K-dependent activation of the atypical PKC isoform PKC-also contributes to p70S6 kinase activation and growth.
The evidence supporting the sequential activation of PI3K, PDK-1, and PKC-leading to IGF-I-induced p70S6 kinase activation and proliferation can be summarized as follows: 1) activation of PI3K was blocked by the PI3K inhibitor but not affected by the PDK-1, PKC-, or p70S6 kinase antagonists; 2) both the phosphorylation and activation of PDK-1 were abolished by the PI3K inhibitor or the PDK-1 inhibitor and were inhibited by the PKC-inhibitor but were not affected by the p70S6 kinase antagonist or expression of kinase-inactive Akt; 3) phosphorylation of PKC-was blocked by the PI3K inhibitor and the PDK-1 inhibitor but was not affected by the p70S6 kinase antagonist or kinase-inactive Akt; 4) phosphorylation of p70S6 kinase(Thr 421 /Ser 424 ) was blocked by the PI3K inhibitor and the p70S6 kinase inhibitor and was partially inhibited by the PKC-inhibitor but was not affected by the PDK-1 inhibitor or kinase-inactive Akt; 5) phosphorylation of p70S6 kinase (Thr 229 ) and p70S6 kinase-(Thr 389 ), activation of p70S6 kinase, and cellular proliferation were blocked by the PI3K, PDK-1, and p70S6 kinase inhibitors and were partially inhibited by the PKC-inhibitor but were not affected by kinase-inactive Akt.
PDK-1, a serine/threonine kinase, links the activation of PI3K and Akt. PDK-1 can also phosphorylate and activate other PI3K-dependent effectors: atypical PKC isoforms and p70S6 kinase. PDK-1 was initially thought to be constitutively active, associated with the plasma membrane, and not subject to growth factor (including IGF-I)-induced phosphorylation or activation (12) . The findings of the current study corroborate and extend more recent information showing that insulin (10) and IGF-I (this study) can induce the phosphorylation of PDK-1 on Ser 241 . Mutants of PDK-1 with disrupted pleckstrin homology domains that do . C: expression of kinase-inactive Akt1(K179M) inhibited the ability of IGF-I to elicit phosphorylation of mTOR(Ser 2448 ) but had no effect on the phosphorylation of PI3K, PDK-1, or PKC-. (34) . These mechanisms do not appear to operate in human intestinal smooth muscle cells, because the p38 MAPK and the MKK1/2 inhibitors do not affect the ability of IGF-I to phosphorylate Akt. Interestingly, activation of Akt does not appear to be a requirement for IGF-I-mediated p70S6 kinase activation or proliferation of human intestinal muscle cells. In cells expressing kinase-inactive Akt1(K179M), IGF-I retained its ability to activate p70S6 kinase and to stimulate proliferation. Activation of Akt by IGF-I in human intestinal muscle cells likely regulates other cellular processes, such as inhibition of apoptosis, a process that has also been observed in this and other cell types (23, 27) .
The homologous atypical PKC isoforms PKC-and PKC-are downstream targets in the PI3K pathway. PI3K-dependent activation of PKC-occurs through three interrelated mechanisms: PDK-1-dependent phosphorylation of PKC-on Thr 410 in the activation loop, autophosphorylation of Thr 560 , and phosphorylation-independent conformational relief of pseudosubstrate inhibition (perhaps via interaction with PIP 3 ) (44) . Evidence that PKC-represents a physiological target of PDK-1 comes from PDK-1-deficient embryonic stem cells that show markedly decreased levels of conventional (PKC-␣, PKC-␤1, PKC-␥) and novel (PKC-␦, PKC-⑀) PKC isoforms compared with PDK-1-positive cells (4) . In contrast, levels of atypical PKCare unchanged, but PKC-cannot be phosphorylated on Thr
410
. IGF-I-mediated proliferation has been shown to involve the atypical PKC isoform PKC-in rat adipocytes (45) and in the rat clonal ␤-cell line RIN 1046-38 (19) . In the present study, IGF-I elicited phosphorylation of atypical PKC-on Thr 410 of the activation loop and/or PKC-on the homologous residue Thr 403 . Activation of PKC-/ by IGF-I participated in p70S6 kinase activation and proliferation of muscle, and these effects were inhibited by the cell-permeant PKC-pseudosubstrate inhibitor myr-PKC--PS (which also blocks the effects of PKC-). These two atypical PKC isoforms appear to act interchangeably in their ability to mediate PI3K-dependent cellular processes such as Glut4 translocation in response to insulin or serum-induced activation of p70S6 kinase (6). This is not to say that conventional and novel PKC isoforms are not regulated by PDK-1 (see above) or do not contribute to the complex mechanism of p70S6 kinase activation and regulation of proliferation.
mTOR is a constitutively active kinase that plays a permissive role in regulating p70S6 kinase activity and thus the ribosomal biogenesis necessary for cell division. mTOR senses the level of amino acids and ATP that are available to the cell (13, 38) . The current study shows that basal levels of mTOR(Ser 2448 ) phosphorylation can be augmented by IGF-I via an Akt-dependent mechanism as has been shown for insulin (37) . Akt-dependent mTOR(Ser 2448 ) phosphorylation does not appear to regulate p70S6 kinase activity, however. Other investigators have shown that mutation of mTOR (Ser 2448 ) to the nonphosphorylated alanine, stimulation with mitogens, withdrawal of amino acids, or treatment with rapamycin all have little affect on mTOR kinase activity (17, 38) . Deletion of the domain surrounding Ser 2448 in mTOR (amino acids 2430-2450), in fact, increases p70S6 kinase activity, suggesting that a repressor function for mTOR resides within this region (41) . The rapamycin-FKBP12 gain-of-function complex inhibits signaling downstream of mTOR by disinhibiting the effects of mTOR on protein phosphatase 2A (PP2A) (33) , which is normally associated with p70S6 kinase and in an inactive form. Once activated, PP2A rapidly dephosphorylates numerous residues of p70S6 kinase with Thr 389 dephosphorylation, most closely paralleling the loss of p70S6 kinase activity (32) . Although addition of rapamycin to human intestinal smooth muscle cells did affect IGF-I-induced mTOR activity, this effect was a minor one. Similar effects of rapamycin have been observed in 3T3 L1 adipocytes treated with insulin (39) . mTOR has also been shown to directly phosphorylate p70S6 kinase on Thr 389 in HEK-293 cells (8) . The present study supports the view that mTOR functions in a coregulatory fashion with the PI3K-dependent signaling pathway involving PDK-1 and PKC-activation. Activation of both pathways is required for p70S6 kinase activation and cell proliferation to occur.
In summary, the present study shows that, in human intestinal smooth muscle cells, IGF-I activates a sequence of events consisting of initial PI3K activation followed by PDK-1 and PKC-phosphorylation and activation that leads to phosphorylation of specific residues within p70S6 kinase that result in full p70S6 kinase activation and proliferation. PI3K, perhaps via PKC-/, regulates phosphorylation of serine/threonine residues in the autoinhibitory domain of p70S6 kinase. PI3K-dependent activation of PDK-1 and PDK-1-dependent PKC-/ activation, in turn, regulate phosphorylation of serine/threonine residues in the catalytic domain of p70S6 kinase, activation of p70S6 kinase, and muscle cell growth. IGF-I-induced Akt activation, although sufficient to increase mTOR(Ser 2448 ) phosphorylation, does not significantly contribute to the regulation of mTOR kinase activity and is not required for either IGF-I-induced p70S6 kinase activation or cell proliferation to occur.
